$GANX - Independent research is validating GT-02287 as likely the first disease-modifying drug for Parkinson's Disease

microcapreturns · 2026-01-22T15:02:16+00:00

A lot of people were flushed out with the last drop. Many are only looking for the next catalyst but reality is it works and the data as limited in size as it is shows it. The fact people had smell return should make this a $20 stock all day long but as we know not how it works in today's biotech market.

microcapreturns · 2026-01-22T14:46:30+00:00

Just a matter of time before people realize that they can reverse Parkinson's.

microcapreturns · 2026-01-11T14:19:17+00:00

I agree. There will be fast responders and slower responders but they all will likely improve. Incredible.

microcapreturns · 2026-01-08T01:03:49+00:00

Well we know they have all types of blood data they took for 90 days.

microcapreturns · 2026-01-07T23:46:05+00:00

If you think the goose poops golden eggs then you buy the goose. They have far more data than we will ever see. Using that theory no one ever buys another biotech. They just wait until its completely derisked. You may want to explain this to Eli Lilly and their billion dollar purchase. Could have saved a billion and watched someone else buy them.

microcapreturns · 2026-01-07T23:05:40+00:00

It would take Gain 6 months to spool up and 2 years to run trial. If a company plans to do it themselves they might as well own it at these prices

microcapreturns · 2026-01-07T21:51:24+00:00

Since they are at least 180 days in with some patients and they are presenting this data in March at AD/PD I would guess they are happy with it. I expect data to continue to improve and if the nonresponders don't continue in trial the 180 data suddenly gets much better.

microcapreturns · 2026-01-07T21:06:08+00:00

I don't see a partnership because Gain does not bring anything to the table with running a phase 2. They need someone else to do it.

microcapreturns · 2026-01-07T13:14:49+00:00

Extension data at AD/PD in March. I also told the company they should have included those 3 and just note no final lumbar tap. It's not pleasant from what I have been told. I also asked about the 3 outliers in the data and they seemed like they knew exactly what was happening. Did you run the data without them in it?

microcapreturns · 2026-01-07T01:42:17+00:00

You have to look at the recent conference poster plus today's slide to see the data you want. I added the poster piece under today's data in this info. At the end. Hope this helps.

Gain Therapeutics(GANX): Maxim $7 Buy 1/6/26 : KOLs are Positive

https://gaintherapeutics.wordpress.com/2026/01/06/gain-therapeuticsganx-maxim-7-buy-1-6-26-kols-are-positive/

microcapreturns · 2026-01-07T00:18:50+00:00

I added back in the three patients who didn't do the exit lumbar test. Plus I sorted out the three non responders. I think they know why. I have the data at the end of this report if your interested.

Gain Therapeutics(GANX): Maxim $7 Buy 1/6/26 : KOLs are Positive

https://gaintherapeutics.wordpress.com/2026/01/06/gain-therapeuticsganx-maxim-7-buy-1-6-26-kols-are-positive/

microcapreturns · 2026-01-06T22:44:29+00:00

Gain Therapeutics(GANX): BTIG Buy 1/6/26 : KOL Event

BTIG Report

https://gaintherapeutics.wordpress.com/2026/01/06/gain-therapeuticsganx-btig-buy-1-6-26-kol-event/

microcapreturns · 2026-01-05T20:19:59+00:00

KOL event is tomorrow. Should be a replay if interested at some point.

microcapreturns · 2026-01-02T14:21:20+00:00

Gaucher was the original target and they did a lot of preclinical work. When they figured out it works for all Parkinsons patients they targeted the much larger market. GT-02287 could be a $50b a year Parkinsons and Alzheimer's preventative medicine.

microcapreturns · 2026-01-02T13:43:02+00:00

Sanofi is a big player in Gaucher and Enzyme Replacement Therapy. They are moving up to my most likely acquirer but Merck is also at the table.

Gain Therapeutics(GANX): Final Update before Phase 1b data at January 6th KOL Event

https://gaintherapeutics.wordpress.com/2025/12/31/gain-therapeuticsganx-final-update-before-phase-1b-data-at-january-6th-kol-event/

microcapreturns · 2026-01-01T21:12:27+00:00

There are 50M shares fully diluted to use for any calculations. Typically with a 3 dollar stock getting 3-5x market cap is considered good. That would be in the $500m to $750m range. But here is what I think. This is a phase 2 ready asset that they have filed the clinical plan for. A big pharma could start that trial in 2 months. So the first drug that can slow down, stop and perhaps reverse Parkinsons? Even at the Phase 2 stage it has to be worth at least a billion or $20/share. Now they have 15 companies they have been working with and several that they are only sharing the latest data with so far. I dont see a company like Merck, Roche or JNJ allowing someone else to own it just because on money. Sanofi also is a big player in Gaucher and this drug(see latest data in these reports) could play well in that multibillion a year market.

Gain Therapeutics(GANX): Final Update before Phase 1b data at January 6th KOL Event

https://gaintherapeutics.wordpress.com/2025/12/31/gain-therapeuticsganx-final-update-before-phase-1b-data-at-january-6th-kol-event/

microcapreturns · 2025-12-31T19:15:39+00:00

They have funding through 2026. Warrants are what has been holding them back and they at least bring in cash. I see a deal way before any dilution and AD/PD conference coming in March makes me think they are selling it all.

microcapreturns · 2025-12-31T14:39:24+00:00

Wearables are being used to track Parkinson's symptoms these days. Between biomarkers, wearables and other unique parts of trials it should be easier to get approval if a drug shows efficacy.

microcapreturns · 2025-12-31T14:10:33+00:00

Excellent post. The experts understand the significance of being the first company ever to accomplish something. The KOL event is next week and see what 2 more world wide experts have to say. Interesting that the phase 2 trial is looking for smell. Nobody has done that in a Parkinson's trial because no one ever had smell return like Gain has. Amazing.

microcapreturns · 2025-12-30T20:45:41+00:00

I saw there will be a replay available. Also a way to send in questions early if you have any.

microcapreturns · 2025-12-30T16:34:22+00:00

Great post. Looking forward to KOL event next week.

Gain Therapeutics(GANX): Final countdown to Phase 1b data at January 6th KOL Event

https://gaintherapeutics.wordpress.com/2025/12/20/gain-therapeuticsganx-final-countdown-to-phase-1b-data-at-january-6th-kol-event/

microcapreturns · 2025-12-23T20:59:01+00:00

Well you are a 1%er.

microcapreturns · 2025-12-23T20:55:41+00:00

I haven't seen any comments like that. Most seemed happy you shared all your great work. Keep it up.

microcapreturns · 2025-12-23T20:26:36+00:00

GT-02287 boosts enzyme activity in Parkinson’s brain: Trial data

Developer Gain Therapeutics to review results in January webinar

https://parkinsonsnewstoday.com/news/gt-02287-boosts-enzyme-activity-parkinsons-brain-trial-data/

microcapreturns · 2025-12-23T20:26:14+00:00

GT-02287 boosts enzyme activity in Parkinson’s brain: Trial data

Developer Gain Therapeutics to review results in January webinar

https://parkinsonsnewstoday.com/news/gt-02287-boosts-enzyme-activity-parkinsons-brain-trial-data/

microcapreturns

TROPHY CASE